» Articles » PMID: 29048462

Obesity-induced Vascular Dysfunction and Arterial Stiffening Requires Endothelial Cell Arginase 1

Overview
Journal Cardiovasc Res
Date 2017 Oct 20
PMID 29048462
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Elevation of arginase activity has been linked to vascular dysfunction in diabetes and hypertension by a mechanism involving decreased nitric oxide (NO) bioavailability due to L-arginine depletion. Excessive arginase activity also can drive L-arginine metabolism towards the production of ornithine, polyamines, and proline, promoting proliferation of vascular smooth muscle cells and collagen formation, leading to perivascular fibrosis. We hypothesized that there is a specific involvement of arginase 1 expression within the vascular endothelial cells in this pathology.

Methods And Results: To test this proposition, we used models of type 2 diabetes and metabolic syndrome. Studies were performed using wild type (WT), endothelial-specific arginase 1 knockout (EC-A1-/-) and littermate controls(A1con) mice fed high fat-high sucrose (HFHS) or normal diet (ND) for 6 months and isolated vessels exposed to palmitate-high glucose (PA/HG) media. Some WT mice or isolated vessels were treated with an arginase inhibitor, ABH [2-(S)-amino-6-boronohexanoic acid. In WT mice, the HFHS diet promoted increases in body weight, fasting blood glucose, and post-prandial insulin levels along with arterial stiffening and fibrosis, elevated blood pressure, decreased plasma levels of L-arginine, and elevated L-ornithine. The HFHS diet or PA/HG treatment also induced increases in vascular arginase activity along with oxidative stress, reduced vascular NO levels, and impaired endothelial-dependent vasorelaxation. All of these effects except obesity and hypercholesterolemia were prevented or significantly reduced by endothelial-specific deletion of arginase 1 or ABH treatment.

Conclusion: Vascular dysfunctions in diet-induced obesity are prevented by deletion of arginase 1 in vascular endothelial cells or arginase inhibition. These findings indicate that upregulation of arginase 1 expression/activity in vascular endothelial cells has an integral role in diet-induced cardiovascular dysfunction and metabolic syndrome.

Citing Articles

Promotion of nitric oxide production: mechanisms, strategies, and possibilities.

Gonzalez M, Clayton S, Wauson E, Christian D, Tran Q Front Physiol. 2025; 16:1545044.

PMID: 39917079 PMC: 11799299. DOI: 10.3389/fphys.2025.1545044.


Arginase 1 genetic variation is associated with the risk of vascular complications in type 2 diabetes.

Chen X, Li L, Ma S, Ling C, Lai J, Yao H Biomark Med. 2025; 19(3):63-72.

PMID: 39885775 PMC: 11792801. DOI: 10.1080/17520363.2025.2455924.


Genetic deletion of 12/15 lipoxygenase delays vascular remodeling and limits cardiorenal dysfunction after pressure overload.

Lee D, Kain V, Wang D, Rokosh D, Prabhu S, Halade G J Mol Cell Cardiol Plus. 2025; 5():100046.

PMID: 39802176 PMC: 11708313. DOI: 10.1016/j.jmccpl.2023.100046.


Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition.

Marzeta-Assas P, Jacenik D, Zaslona Z Int J Mol Sci. 2024; 25(18).

PMID: 39337272 PMC: 11431790. DOI: 10.3390/ijms25189782.


Endothelial Dysfunction in Obesity and Therapeutic Targets.

Engin A Adv Exp Med Biol. 2024; 1460:489-538.

PMID: 39287863 DOI: 10.1007/978-3-031-63657-8_17.


References
1.
Lange P, Langley B, Lu P, Ratan R . Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J Nutr. 2004; 134(10 Suppl):2812S-2817S. DOI: 10.1093/jn/134.10.2812S. View

2.
Li H, Meininger C, Hawker Jr J, Haynes T, Mistry S, Morris Jr S . Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2000; 280(1):E75-82. DOI: 10.1152/ajpendo.2001.280.1.E75. View

3.
Hatzoglou M, Fernandez J, Yaman I, Closs E . Regulation of cationic amino acid transport: the story of the CAT-1 transporter. Annu Rev Nutr. 2004; 24:377-99. DOI: 10.1146/annurev.nutr.23.011702.073120. View

4.
Katusic Z, Duscio L, Nath K . Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci. 2008; 30(1):48-54. PMC: 2637534. DOI: 10.1016/j.tips.2008.10.003. View

5.
Bhatta A, Yao L, Toque H, Shatanawi A, Xu Z, Caldwell R . Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function. PLoS One. 2015; 10(3):e0121727. PMC: 4373900. DOI: 10.1371/journal.pone.0121727. View